InvestorIdeas.com, a leading online global investor resource, issued the Sector Close Up for Pharmaceutical and Biotech Stocks. In particular, InvestorIdeas.com focused their review on Gene therapy, which allows for the introduction of genetic material into a person’s cells to fight or prevent disease.
Benda Pharmaceutical, INC (BPMA.OB), a China based pharmaceutical company recognized for their gene therapy treatment “Gendicine”, is the first such company to market gene therapy medicine for the treatment of cancer. Gendicine has been used to treat more than 50 types of malignant tumors in over 6,000 patients, including 1,800 foreigners. According to Clinical Trails on 135 patients that were affected by head and neck tumors, 64% had their tumors eliminated after one month of Gendicine treatment — a 340% increase in efficiency relative to traditional treatments.
According to Justin Davis from After Market Support, LLC, “The addition of Gendicine® to Benda’s drug portfolio thrusts the Company to the leading edge of both the gene therapy revolution and the world’s ongoing fight against cancer. As the first cancer-treating gene therapy drug available to the public — anywhere — Gendicine® has garnered international attention and has turned both the medical and investing spotlights directly on Benda. Moreover, the demonstrated efficacy of Gendicine® has already translated into immediate financial returns for Benda — $3.8 MM in orders in one day after a recent medical conference in China. With the Company preparing to present the latest independent findings to an international gene therapy symposium in Europe, Benda finds itself at the cusp of what could become a global phenomenon.”
Another player in the gene therapy arena is Introgen Therapeutics, Inc, a biopharmaceutical company focused on targeting molecular therapies for the treatment of cancer and other diseases. Introgen’s drug, called ADVEXIN, is currently in Phase 3 clinical trials for the treatment of head and neck cancer and Li-Fraumeni Syndrome. According to the Company, regulatory filings in both the United States and in Europe are expected to be completed by the end of 2007.
Let us hear your thougths below: